Jessica Altman, MD
Enriched profileProfessor of Medicine, Division of Hematology and Oncology; Director, Acute Leukemia Program, Robert H. Lurie Comprehensive Cancer Center · Northwestern University Feinberg School of Medicine
Jessica Altman is Professor of Medicine, Division of Hematology and Oncology; Director, Acute Leukemia Program, Robert H. Lurie Comprehensive Cancer Center at Northwestern University Feinberg School of Medicine. OpenAlex indexes 404 publications with 19,699 citations (h-index 65); ClinicalTrials.gov lists 10 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 25 Aug 2026
Overview
Updated 14 Oct 2026
Jessica K. Altman, MD, is Professor of Medicine, Division of Hematology and Oncology at Northwestern University Feinberg School of Medicine / Robert H. Lurie Comprehensive Cancer Center. The public record shows 404 publications with 19,699 citations (h-index 65), centered on MDS / MPN, Leukemia (AML/ALL/CML/CLL). It also documents an investigator role on 10 registered clinical trials, industry payments reported by 23 companies.
- Most recent indexed publication: 2025 · Journal of clinical oncology
- Top research focus: MDS / MPN
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 23 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 10 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Sponsor: Crossbow Therapeutics, Inc.
- Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
Sponsor: SystImmune Inc.
- Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 14 Oct 2026
23 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Inc.Program year20259 payments
- Janssen Global Services, LLCProgram year20252 payments
- Genentech USA, Inc.Program year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
36.4%CD38-directed Cytolytic Antibody27.4%Daratumumab100%Part B, office-administered≥23 patientsProteasome Inhibitor7.3%Bortezomib100%Part B, office-administered≥26 patients+ 3 more classes in this area
Dermatology
26.1%Corticosteroid25.9%Methylprednisolone sodium succinate100%Part B, office-administered≥25 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor0.1%Acyclovir100%Part D≥11 patientsAnti-infectives
19%Human Immunoglobulin G18.7%Immune globulin100%Part B, office-administered≥40 patientsAzole Antifungal0.1%Fluconazole100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.
Journal of clinical oncology
Clinical Trial2025 - Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)/t(16;16)/CBFB::MYH11.
European journal of haematology
Article2024 - PRL2 Phosphatase Promotes Oncogenic KIT Signaling in Leukemia Cells through Modulating CBL Phosphorylation.
Molecular cancer research
Article2024 - Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.
Blood advances
Clinical Trial2023
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jessica-altman-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - X / Twitter
x.com/jaltmanmd
Mentions by others
where others cite or feature them- Other
ashpublications.org/ashclinicalnews/news/4664/Pulling-Back-the-Curtain-Jessica-K-Altman-MD
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ashpublications.org ↗ - Other
onclive.com/authors/jessica-k-altman-md-northwestern-university
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - X / Twitter
Active X (Twitter) account @jaltmanmd, posting on ASH conference activity and Northwestern hematology/oncology community
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
- Board Certified
Hematology, American Board of Internal Medicine
Editorial & leadership roles
journal and society appointments- Chair
Steering Committee, AML/MDS MATTERS Program
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hmpglobalevents.com ↗ - Member
NCCN Acute Myeloid Leukemia Panel
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hmpglobalevents.com ↗ - Member
NCCN Chronic Myelogenous Leukemia Panel
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hmpglobalevents.com ↗ - Chair
Clinical Trial Audit Committee, Robert H. Lurie Comprehensive Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hmpglobalevents.com ↗ - Member
American Society of Hematology (ASH)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ashpublications.org ↗ - Active investigator
ECOG-ACRIN cooperative group; site PI, NCI MyeloMATCH screening trial
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clinicaltrials.gov ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →feinberg.northwestern.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.northwestern.edu ↗
Media & interviews
press, podcasts and appearances- Feature profile: "Pulling Back the Curtain: Jessica K. Altman, MD"
ASH Clinical News, American Society of Hematology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ashpublications.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
- Regular video/print contributor
OncLive (FLT3-mutated AML, triplet therapies in AML, and other leukemia topics)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Clyde Yancy, MD
Northwestern University Feinberg School of Medicine
Martin Tallman, MD
Northwestern University Feinberg School of Medicine
Al Benson, MD
Northwestern University Feinberg School of Medicine
Sanjiv Shah, MD
Northwestern University Feinberg School of Medicine
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center